December 20, 2017

Sentimag / Sienna+ – Magnetic lymph node localisation

Many treatments for early-stage cancer involve ‘sentinel lymph node biopsy’, or SLNB. This method, which identifies the lymph nodes with the highest potential for harbouring metastases, helps to determine the nodal stage of the cancer and make informed decisions for surgery and subsequent treatment. Standard SLNB uses radioisotopes for sentinel node localisation. We offer an effective clinical solution that uses safe magnetic fields instead. This eliminates concerns related to the safety, workflow and availability associated with ionising radiation. Best practice SLNB is now possible everywhere, with no time restrictions. Our system consists of the Sentimag probe and the Sienna+ magnetic tracer. First, the tracer is injected into the interstitial tissue to provide a traceable signal. Next, using the Sentimag probe, you locate the sentinel lymph nodes to determine how far the cancer has spread.

Posted in Sentimag-En by ادمین
December 20, 2017

OSNA – Advanced platform for analysing lymph nodes

Nodal status matters

More differentiated information – Supporting better treatment decisions Lymph node status is one of the most important prognostic factors in many cancers and a key criterion for surgical and therapeutic decisions. Analysing lymph node tissue reliably and accuracy is therefore crucial for detecting metastases. Routine practice in histopathology analyses only a limited amount of tissue and therefore provides only limited information, which might not reflect the real metastatic burden. OSNA – One Step Nucleic Acid Amplification – is an automated molecular diagnostic assay that analyses the entire lymph node tissue. The reaction is based on rapid nucleic acid amplification technology (RT-LAMP*) to quantify Cytokeratin 19 (CK19) mRNA

Posted in OSNA-En by ادمین
December 20, 2017

Sienna+ – An effective clinical solution


  • • Perform best practice SLNB in any clinical setting

  • • Eliminate issues with radioactive materials; reach equivalent clinical outcomes

  • • As a surgeon, organise and manage the SLNB procedure to suit your needs

  • • Inject the tracer at the best moment, up to seven days in advance

  • • No evidence of anaphylaxis with interstitial tracer

Posted in Sienna-En by ادمین
December 18, 2017

Magseed/Lesion Localisation

The clinical procedures leading to the removal of a tumour include marking the lesion for location during surgery. The current standard of care for breast tumours is for a hooked guide wire to be fixed into the tumour. The tail of the guide wire protrudes from the breast and is taped to the patient, and the surgeon can later follow the wire to remove the tumour and along with a margin of healthy tissue.

If the guide wire moves in between implantation and surgery, it could result in the patient requiring additional surgery to correctly remove a safe margin of healthy tissue. This movement can also lead to the removal of more tissue than desired. In addition, due to the open incision created by the guide wire, surgery must be performed on the same day, creating workflow challenges for the hospital.

Many hospitals are now implementing radioactive seeds to replace the breast guide wire. Thi

Posted in Magseed-En by ادمین

Powered by